ALPRAZOLAM- alprazolam tablet Sandoz Inc Reference Label Set Id: 210bf21f-340b-4fa1-9062-c67465ee051f

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ALPRAZOLAM TABLETS safely and effectively. See full prescribing information for ALPRAZOLAM TABLETS. ALPRAZOLAM tablets, for oral use, CIV Initial U.S. Approval: 1981

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS

See full prescribing information for complete boxed warning.

- Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation. (5.1, 7.1)
- The use of benzodiazepines, including alprazolam tablets, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Before prescribing alprazolam tablets and throughout treatment, assess each patient's risk for abuse, misuse, and addiction. (5.2)
- Abrupt discontinuation or rapid dosage reduction of alprazolam tablets after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue alprazolam tablets or reduce the dosage. (2.2, 5.3)

-----RECENT MAJOR CHANGES ------

Warnings and Precautions (5.8) 1/2023

Alprazolam tablets are a benzodiazepine indicated for the:

- Acute treatment of generalized anxiety disorder in adults. (1)
- Treatment of panic disorder with or without agoraphobia in adults. (1)

------DOSAGE AND ADMINISTRATION

- Generalized Anxiety Disorder:(2.1)
- \odot Recommended starting oral dosage is 0.25 mg to 0.5 mg three times daily.
- Dosage may be increased, at intervals of every 3 to 4 days, to a maximum recommended daily dose of 4 mg, given in divided doses.
- Use the lowest possible effective dose and frequently assess the need for continued treatment.
- **Panic Disorder:** Recommended starting oral dosage is 0.5 mg three times daily. The dosage may be increased at intervals of every 3 to 4 days in increments of no more than 1 mg per day. (2.2)
- When tapering, decrease dosage by no more than 0.5 mg every 3 days. Some patients may require an even slower dosage reduction. (2.3, 5.2)
- See the Full Prescribing Information for the recommended dosage in geriatric patients, patients with hepatic impairment, and with use with ritonavir. (2.4, 2.5, 2.6)

DOSAGE FORMS AND STRENGTHS			
Tablets: 0.25 mg, 0.5 mg, 1 mg, and 2 mg (3)			
CONTRAINDICATIONS			

- Known hypersensitivity to alprazolam or other benzodiazepines. (4)
- Concomitant use with strong cytochrome P450 3A (CYP3A) inhibitors, except ritonavir. (4, 5.5, 7.1)

 Effects on Driving and Operating Machinery: Patients receiving alprazolam should be cautioned against operating machinery or driving a motor vehicle, as well as avoiding concomitant use of alcohol and other central nervous system (CNS) depressant drugs. (5.4) Patients with Depression: Exercise caution in patients with signs or symptoms of depression. Prescribe the least number of tablets feasible to avoid intentional overdosage. (5.6) Neonatal Sedation and Withdrawal Syndrome: Alprazolam use during pregnancy can result in neonatal sedation and/or neonatal withdrawal. (5.8, 8.1)
ADVERSE REACTIONS
The most common adverse reactions reported in clinical trials for generalized anxiety disorder and panic disorder (incidence \geq 5% and at least twice that of placebo) include: impaired coordination, hypotension, dysarthria, and increased libido. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
DRUG INTERACTIONS
 Use with Opioids: Increase the risk of respiratory depression. (7.1) Use with Other CNS Depressants: Produces additive CNS depressant effects. (7.1) Use with Digoxin: Increase the risk of digoxin toxicity. (7.1) Use with CYP3A Inhibitors (except ritonavir): Increase the risk of adverse reactions of alprazolam. (4, 5.5, 7.1) Use with CYP3A Inducers: Increase the risk of reduced efficacy of alprazolam. (7.1)
Lactation: Breastfeeding not recommended. (8.2)
See 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Revised: 11/2023

FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS 1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

- 2.1 Dosage in Generalized Anxiety Disorder
- 2.2 Dosage in Panic Disorder
- 2.3 Discontinuation or Dosage Reduction of Alprazolam
- 2.4 Dosage Recommendations in Geriatric Patients
- 2.5 Dosage Recommendations in Patients with Hepatic Impairment
- 2.6 Dosage Modifications for Drug Interactions

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Risks from Concomitant Use with Opioids
- 5.2 Abuse, Misuse, and Addiction
- 5.3 Dependence and Withdrawal Reactions
- 5.4 Effects on Driving and Operating Machinery
- 5.5 Interaction with Drugs that Inhibit Metabolism via Cytochrome P450 3A
- 5.6 Patients with Depression
- 5.7 Mania

5.8 Neonatal Sedation and Withdrawal Syndrome

5.9 Risk in Patients with Impaired Respiratory Function

6 ADVERSE REACTIONS

- 6.1 Clinical Trials Experience
- 6.2 Postmarketing Experience

7 DRUG INTERACTIONS

- 7.1 Drugs Having Clinically Important Interactions with Alprazolam
- 7.2 Drug/Laboratory Test Interactions

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Hepatic Impairment

9 DRUG ABUSE AND DEPENDENCE

- 9.1 Controlled Substance
- 9.2 Abuse
- 9.3 Dependence

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- 13.2 Animal Toxicology and/or Pharmacology

14 CLINICAL STUDIES

- 14.1 Generalized Anxiety Disorder
- 14.2 Panic Disorder

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS

- Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation[see Warnings and Precautions (5.1), Drug Interactions (7.1)].
- The use of benzodiazepines, including alprazolam tablets, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing alprazolam tablets and throughout treatment, assess each patient's risk for abuse, misuse, and addiction [see Warnings and Precautions (5.2)].
- The continued use of benzodiazepines, including alprazolam tablets, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of alprazolam tablets after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue alprazolam tablets or reduce the dosage [see Dosage and Administration (2.2), Warnings and Precautions (5.3)].

1 INDICATIONS AND USAGE

Alprazolam tablets are indicated for the:

- acute treatment of generalized anxiety disorder (GAD) in adults.
- treatment of panic disorder (PD), with or without agoraphobia in adults.

2 DOSAGE AND ADMINISTRATION

2.1 Dosage in Generalized Anxiety Disorder

The recommended starting oral dosage of alprazolam for the acute treatment of patients with GAD is 0.25 mg to 0.5 mg administered three times daily. Depending upon the response, the dosage may be adjusted at intervals of every 3 to 4 days. The maximum recommended dosage is 4 mg daily (in divided doses).

Use the lowest possible effective dose and frequently assess the need for continued treatment [see Warnings and Precautions (5.2)].

2.2 Dosage in Panic Disorder

The recommended starting oral dosage of alprazolam for the treatment of PD is 0.5 mg three times daily. Depending on the response, the dosage may be increased at intervals of every 3 to 4 days in increments of no more than 1 mg per day.

Controlled trials of alprazolam in the treatment of panic disorder included dosages in the range of 1 mg to 10 mg daily. The mean dosage was approximately 5 mg to 6 mg daily. Occasional patients required as much as 10 mg per day.

For patients receiving doses greater than 4 mg per day, periodic reassessment and consideration of dosage reduction is advised. In a controlled postmarketing dose-response study, patients treated with doses of alprazolam greater than 4 mg per day for 3 months were able to taper to 50% of their total maintenance dose without apparent loss of clinical benefit.

The necessary duration of treatment for PD in patients responding to alprazolam is unknown. After a period of extended freedom from panic attacks, a carefully supervised tapered discontinuation may be attempted, but there is evidence that this may often be difficult to accomplish without recurrence of symptoms and/or the manifestation of withdrawal phenomena [see Dosage and Administration (2.3)].

2.3 Discontinuation or Dosage Reduction of Alprazolam

To reduce the risk of withdrawal reactions, use a gradual taper to discontinue alprazolam or reduce the dosage. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the previous tapered dosage level. Subsequently decrease the dosage more slowly [see Warnings and Precautions (5.3), Drug Abuse and Dependence (9.3)].

Reduced the dosage by no more than 0.5 mg every 3 days. Some patients may benefit from an even more gradual discontinuation. Some patients may prove resistant to all discontinuation regimens.

In a controlled postmarketing discontinuation study of panic disorder patients which compared the recommended taper schedule with a slower taper schedule, no difference was observed between the groups in the proportion of patients who tapered to zero dose; however, the slower schedule was associated with a reduction in symptoms associated with a withdrawal syndrome.

2.4 Dosage Recommendations in Geriatric Patients

In geriatric patients, the recommended starting oral dosage of alprazolam is 0.25 mg, given 2 or 3 times daily. This may be gradually increased if needed and tolerated. Geriatric patients may be especially sensitive to the effects of benzodiazepines. If adverse reactions occur at the recommended starting dosage, the dosage may be reduced [see Use in Specific Populations (8.5), Clinical Pharmacology (12.3)].

2.5 Dosage Recommendations in Patients with Hepatic Impairment

In patients with hepatic impairment, the recommended starting oral dosage of alprazolam is 0.25 mg, given 2 or 3 times daily. This may be gradually increased if needed and tolerated. If adverse reactions occur at the recommended starting dose, the dosage may be reduced [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)].

2.6 Dosage Modifications for Drug Interactions

Alprazolam should be reduced to half of the recommended dosage when a patient is started on ritonavir and alprazolam together, or when ritonavir administered to a patient treated with alprazolam. Increase the alprazolam dosage to the target dose after 10 to 14 days of dosing ritonavir and alprazolam together. It is not necessary to reduce alprazolam dose in patients who have been taking ritonavir for more than 10 to 14 days.

Alprazolam is contraindicated with concomitant use of all strong CYP3A inhibitors, except ritonavir [see Contraindications (4), Warnings and Precautions (5.5)].

3 DOSAGE FORMS AND STRENGTHS

Alprazolam tablets are available as:

- 0.25 mg: white, oval, debossed "GG 256" on one side and scored on the reverse side
- 0.5 mg: peach, oval, debossed "GG 257" on one side and scored on the reverse side
- 1 mg: blue, oval, debossed "GG 258" on one side and scored on the reverse side
- 2 mg: white, rectangular, multi-scored, debossed "GG 249" on one side and plain on the reverse side

4 CONTRAINDICATIONS

Alprazolam is contraindicated in patients:

- with known hypersensitivity to alprazolam or other benzodiazepines. Angioedema has been reported [see Adverse Reactions (6.2)].
- taking strong cytochrome P450 3A (CYP3A) inhibitors (e.g., ketoconazole, itraconazole), except ritonavir [see Dosage and Administration (2.6), Warnings and Precautions (5.5), Drug Interactions (7.1)]

5 WARNINGS AND PRECAUTIONS

5.1 Risks from Concomitant Use with Opioids

Concomitant use of benzodiazepines, including alprazolam, and opioids may result in profound sedation, respiratory depression, coma, and death. Because of these risks, reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate.

Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. If a decision is made to prescribe alprazolam concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use, and follow patients closely for signs and symptoms of respiratory depression and sedation. In patients already receiving an opioid analgesic, prescribe a lower initial dose of alprazolam than indicated in the absence of an opioid and titrate based on clinical response. If an opioid is initiated in a patient already taking alprazolam, prescribe a lower initial dose of the opioid and titrate based upon clinical response.

Advise both patients and caregivers about the risks of respiratory depression and sedation when alprazolam is used with opioids. Advise patients not to drive or operate heavy machinery until the effects of concomitant use with the opioid have been determined [see Drug Interactions (7.1)].

5.2 Abuse, Misuse, and Addiction

The use of benzodiazepines, including alprazolam, exposes users to the risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death [see Drug Abuse and Dependence (9.2)].

Before prescribing alprazolam and throughout treatment, assess each patient's risk for abuse, misuse, and addiction (e.g., using a standardized screening tool). Use of alprazolam, particularly in patients at elevated risk, necessitates counseling about the risks and proper use of alprazolam along with monitoring for signs and symptoms of abuse, misuse, and addiction. Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. If a substance use disorder is suspected, evaluate the patient and institute (or refer them for) early treatment, as appropriate.

5.3 Dependence and Withdrawal Reactions

To reduce the risk of withdrawal reactions, use a gradual taper to discontinue alprazolam or reduce the dosage (a patient-specific plan should be used to taper the dose) [see Dosage and Administration (2.3)].

Patients at an increased risk of withdrawal adverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages, and those who have had longer durations of use.

Acute Withdrawal Reactions

The continued use of benzodiazepines, including alprazolam, may lead to clinically significant physical dependence. Abrupt discontinuation or rapid dosage reduction of alprazolam after continued use, or administration of flumazenil (a benzodiazepine antagonist) may precipitate acute withdrawal reactions, which can be life-threatening (e.g., seizures) [see Drug Abuse and Dependence (9.3)].

Protracted Withdrawal Syndrome

In some cases, benzodiazepine users have developed a protracted withdrawal syndrome with withdrawal symptoms lasting weeks to more than 12 months [see Drug Abuse and Dependence (9.3)].

Certain adverse clinical events, some life-threatening, are a direct consequence of physical dependence to alprazolam. These include a spectrum of withdrawal symptoms; the most important is seizure [see Drug Abuse and Dependence (9.3)]. Even after

relatively short-term use at doses of \leq 4 mg/day, there is some risk of dependence. Spontaneous reporting system data suggest that the risk of dependence and its severity appear to be greater in patients treated with doses greater than 4 mg/day and for long periods (more than 12 weeks). However, in a controlled postmarketing discontinuation study of panic disorder patients who received alprazolam, the duration of treatment (3 months compared to 6 months) had no effect on the ability of patients to taper to zero dose. In contrast, patients treated with doses of alprazolam greater than 4 mg/day had more difficulty tapering to zero dose than those treated with less than 4 mg/day.

In a controlled clinical trial in which 63 patients were randomized to alprazolam and where withdrawal symptoms were specifically sought, the following were identified as symptoms of withdrawal: heightened sensory perception, impaired concentration, dysosmia, clouded sensorium, paresthesias, muscle cramps, muscle twitch, diarrhea, blurred vision, appetite decrease, and weight loss. Other symptoms, such as anxiety and insomnia, were frequently seen during discontinuation, but it could not be determined if they were due to return of illness, rebound, or withdrawal.

Interdose Symptoms

Early morning anxiety and emergence of anxiety symptoms between doses of alprazolam have been reported in patients with panic disorder taking prescribed maintenance doses. These symptoms may reflect the development of tolerance or a time interval between doses which is longer than the duration of clinical action of the administered dose. In either case, it is presumed that the prescribed dose is not sufficient to maintain plasma levels above those needed to prevent relapse, rebound, or withdrawal symptoms over the entire course of the interdosing interval.

5.4 Effects on Driving and Operating Machinery

Because of its CNS depressant effects, patients receiving alprazolam should be cautioned against engaging in hazardous occupations or activities requiring complete mental alertness such as operating machinery or driving a motor vehicle. For the same reason, patients should be cautioned about the concomitant use of alcohol and other CNS depressant drugs during treatment with alprazolam [see Drug Interactions (7.1)].

5.5 Interaction with Drugs that Inhibit Metabolism via Cytochrome P450 3A

The initial step in alprazolam metabolism is hydroxylation catalyzed by cytochrome P450 3A (CYP3A). Drugs that inhibit this metabolic pathway may have a profound effect on the clearance of alprazolam.

Strong CYP3A Inhibitors

Alprazolam is contraindicated in patients receiving strong inhibitors of CYP3A (such as azole antifungal agents), except ritonavir *[see Contraindications (4)]*. Ketoconazole and itraconazole have been shown *in vivo* to increase plasma alprazolam concentrations 3.98 fold and 2.70 fold, respectively.

Dosage adjustment is necessary when alprazolam and ritonavir are initiated concomitantly or when ritonavir is added to a stable dosage of alprazolam [see Dosage and Administration (2.6), Drug Interactions (7.1)].

Drugs demonstrated to be CYP3A inhibitors on the basis of clinical studies involving

alprazolam: nefazodone, fluvoxamine, and cimetidine [see Drug Interaction (7.1), Clinical Pharmacology (12.3)]. Use caution and consider dose reduction of alprazolam, as appropriate, during co-administration with these drugs.

5.6 Patients with Depression

Benzodiazepines may worsen depression. Panic disorder has been associated with primary and secondary major depressive disorders and increased reports of suicide among untreated patients. Consequently, appropriate precautions (e.g., limiting the total prescription size and increased monitoring for suicidal ideation) should be considered in patients with depression.

5.7 Mania

Episodes of hypomania and mania have been reported in association with the use of alprazolam in patients with depression [see Adverse Reactions (6.2)].

5.8 Neonatal Sedation and Withdrawal Syndrome

Use of alprazolam late in pregnancy can result in sedation (respiratory depression, lethargy, hypotonia) and/or withdrawal symptoms (hyperreflexia, irritability, restlessness, tremors, inconsolable crying, and feeding difficulties) in the neonate [see Use in Specific Populations (8.1)]. Monitor neonates exposed to alprazolam during pregnancy or labor for signs of sedation and monitor neonates exposed to alprazolam during during pregnancy for signs of withdrawal; manage these neonates accordingly.

5.9 Risk in Patients with Impaired Respiratory Function

There have been reports of death in patients with severe pulmonary disease shortly after the initiation of treatment with alprazolam. Closely monitor patients with impaired respiratory function. If signs and symptoms of respiratory depression, hypoventilation, or apnea occur, discontinue alprazolam.

6 ADVERSE REACTIONS

The following clinically significant adverse reactions are described elsewhere in the labeling:

- Risks from Concomitant Use with Opioids [see Warnings and Precautions (5.1)]
- Abuse, Misuse, and Addiction [see Warnings and Precautions (5.2)]
- Dependence and Withdrawal Reactions [see Warnings and Precautions (5.3)]
- Effects on Driving and Operating Machinery [see Warnings and Precautions (5.4)]
- Patients with Depression [see Warnings and Precautions (5.6)]
- Neonatal Sedation and Withdrawal Syndrome [see Warnings and Precautions (5.8)]
- Risks in Patients with Impaired Respiratory Function [see Warnings and Precautions (5.9)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data in the two tables below are estimates of adverse reaction incidence among adult patients who participated in:

- 4-week placebo-controlled clinical studies with alprazolam dosages up to 4 mg per day for the acute treatment of generalized anxiety disorder (**Table 1**)
- Short-term (up to 10 weeks) placebo-controlled clinical studies with alprazolam dosages up to 10 mg per day for panic disorder, with or without agoraphobia (Table 2).

Table 1: Adverse Reactions Occurring in ≥1% in Alprazolam-treated Patients
and Greater than Placebo-treated Patients in Placebo-Controlled Trials for
Generalized Anxiety

	Alprazolam n=565	Placebo n=505
Nervous system disorders	41% 21% 2%	22% 19% 1%
Drowsiness Light-headedness Dizziness Akathisia	2% 15% 4%	1% 13% 2%
Gastrointestinal disorders		
Dry mouth Increased salivation		
Cardiovascular disorders Hypotension Skin and subcutaneous tissue disorders	5% 4%	2% 3%
Dermatitis/allergy		

In addition to the adverse reactions (i.e., greater than 1%) enumerated in the table above for patients with generalized anxiety disorder, the following adverse reactions have been reported in association with the use of benzodiazepines: dystonia, irritability, concentration difficulties, anorexia, transient amnesia or memory impairment, loss of coordination, fatigue, seizures, sedation, slurred speech, jaundice, musculoskeletal weakness, pruritus, diplopia, dysarthria, changes in libido, menstrual irregularities, incontinence and urinary retention.

Table 2: Adverse Reactions Occuring in ≥1% in Alprazolam-treated Patients and Greater than Placebo-treated Patients in Placebo-Controlled Trials (Up to 10 Weeks) for Panic Disorder

Alprazolam	Placebo	

	n=1388	n=1231
	77%	43%
Drowsiness	49%	42%
Fatique and Tiredness	40%	18%
Impaired Coordination	33%	30%
Irritability	33%	22%
Memory Impairment	29%	21%
Cognitive Disorder	14%	8%
Decreased Libido	23%	6%
Dysartharia	10%	8%
Confusional state	8%	4%
Increased libido	7%	6%
Change in libido (not	3%	2%
specified)	2%	1%
Disinhibition	2%	1%
Talkativeness		
Derealization		
Controintenting	26%	15%
Gastrointestinal	6%	4%
disorders Constipation	11%	8%
Increased salivation		
Skin and subcutaneous tissue disorders		
Rash		
Other	33%	23%
	28%	24%
Increased appetite	27%	18%
Decreased appetite	23%	17%
Weight gain	12%	9%
Weight loss	11%	9%
Micturition difficulties	7%	4%
Menstrual disorders	2%	1%
Sexual dysfunction		
Incontinence		

In addition to the reactions (i.e., greater than 1%) enumerated in the table above for patients with panic disorder, the following adverse reactions have been reported in association with the use of alprazolam: seizures, hallucinations, depersonalization, taste alterations, diplopia, elevated bilirubin, elevated hepatic enzymes, and jaundice.

Adverse Reactions Reported as Reasons for Discontinuation in Treatment of Panic Disorder in Placebo-Controlled Trials

In a larger database comprised of both controlled and uncontrolled studies in which 641 patients received alprazolam, discontinuation-emergent symptoms which occurred at a rate of over 5% in patients treated with alprazolam and at a greater rate than the

placebo-treated group are shown in **Table 3**.

	Alprazolam-treated Patients n=641
Nervous system disorders	29.5%
Insomnia	19.3%
Light-headedness	17.3%
Abnormal involuntary movement	17.0%
Headache	6.9%
Muscular twitching	6.6%
Impaired coordination	5.9%
Muscle tone disorders	5.8%
Weakness	
Psychiatric disorders	19.2%
Anxiety	18.4%
Fatigue and Tiredness	10.5%
Irritability	10.3%
Cognitive disorder	5.5%
Memory impairment	5.1%
Depression	5.0%
Confusional state	
Gastrointestinal disorders	16.5%
Nausea/Vomiting	13.6%
Diarrhea	10.6%
Decreased salivation	
Metabolism and nutrition disorders	13.3%
Weight loss	12.8%
Decreased appetite	
Dermatological disorders	14.4%
Sweating	
Cardiovascular disorders	12.2%
Tachycardia	
Special Senses	10.0%
Blurred vision	

Table 3: Discontinuation-Emergent Symptom Incidence Reported in ≥5% of Alprazolam-treated Patients and > Placebo-treated Patients

n = number of patients.

There have also been reports of withdrawal seizures upon rapid decrease or abrupt discontinuation of alprazolam [see Warning and Precautions (5.2) and Drug Abuse and Dependence (9.3)].

Paradoxical reactions such as stimulation, increased muscle spasticity, sleep disturbances, hallucinations, and other adverse behavioral effects such as agitation, rage, irritability, and aggressive or hostile behavior have been reported rarely. In many of the spontaneous case reports of adverse behavioral effects, patients were receiving other CNS drugs concomitantly and/or were described as having underlying psychiatric conditions. Should any of the above events occur, alprazolam should be discontinued. Isolated published reports involving small numbers of patients have suggested that patients who have borderline personality disorder, a prior history of violent or aggressive behavior, or alcohol or substance abuse may be at risk for such events. Instances of irritability, hostility, and intrusive thoughts have been reported during discontinuation of alprazolam in patients with posttraumatic stress disorder.

6.2 Postmarketing Experience

The following adverse reactions have been identified during postapproval use of alprazolam. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Endocrine disorders

Hyperprolactinemia

General disorders and administration site conditions

Edema peripheral

Hepatobiliary disorders

Hepatitis, hepatic failure

Investigations

Liver enzyme elevations

Psychiatric disorders

Hypomania, mania

Reproductive system and breast disorders

Gynecomastia, galactorrhea

Skin and subcutaneous tissue disorders

Photosensitivity reaction, angioedema, Stevens-Johnson syndrome

7 DRUG INTERACTIONS

7.1 Drugs Having Clinically Important Interactions with Alprazolam

Table 4 includes clinically significant drug interactions with alprazolam [see Clinical Pharmacology (12.3)].

Opioids	
Clinical implication	The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at gammaaminobutyric acid(GABA _A) sites and opioids interact primarily at mu receptors. When benzodiazepines

Table 4: Clinically Significant Drug Interactions with Alprazolam

	and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related
	respiratory depression exists.
Prevention or management	Limit dosage and duration of concomitant use of alprazolam and opioids, and monitor patients closely for respiratory depression and sedation [see Warnings and Precautions (5.1)].
Examples	Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorpenol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.
CNS Depressants	
Clinical implication	The benzodiazepines, including alprazolam, produce additive CNS depressant effects when coadministered with other CNS depressants.
Prevention or management	Limit dosage and duration of alprazolam during concomitant use with CNS depressants [see Warnings and Precautions (5.3)].
Examples	Psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.
Strong Inhibitors of CYP3	3A (except ritonavir)
Clinical implication	Concomitant use of alprazolam with strong CYP3A inhibitors has a profound effect on the clearance of alprazolam, resulting in increased concentrations of alprazolam and increased risk of adverse reactions [see <i>Clinical Pharmacology (12.3)</i>].
Prevention or management	Concomitant use of alprazolam with a strong CYP3A4 inhibitor (except ritonavir) is contraindicated [see Contraindications (4), Warnings and Precautions (5.5)].
Examples	
	Ketoconazole, itraconazole, clarithromycin
Moderate or Weak Inhibi	
Moderate or Weak Inhibi	 tors of CYP3A Concomitant use of alprazolam with CYP3A inhibitors may increase the concentrations of alprazolam, resulting in increased risk of adverse reactions of alprazolam [see Clinical Pharmacology (12.3)]. Avoid use and consider appropriate dose reduction when alprazolam is coadministered with a moderate or weak CYP3A inhibitor [see Warnings and Precautions (5.5)].
Moderate or Weak Inhibit Clinical implication Prevention or management Examples	tors of CYP3A Concomitant use of alprazolam with CYP3A inhibitors may increase the concentrations of alprazolam, resulting in increased risk of adverse reactions of alprazolam [see <i>Clinical Pharmacology (12.3)</i>]. Avoid use and consider appropriate dose reduction when alprazolam is coadministered with a moderate or weak
Moderate or Weak Inhibit Clinical implication Prevention or management Examples CYP3A Inducers	 tors of CYP3A Concomitant use of alprazolam with CYP3A inhibitors may increase the concentrations of alprazolam, resulting in increased risk of adverse reactions of alprazolam [see Clinical Pharmacology (12.3)]. Avoid use and consider appropriate dose reduction when alprazolam is coadministered with a moderate or weak CYP3A inhibitor [see Warnings and Precautions (5.5)]. Nefazodone, fluvoxamine, cimetidine, erythromycin
Moderate or Weak Inhibit Clinical implication Prevention or management Examples	tors of CYP3AConcomitant use of alprazolam with CYP3A inhibitors may increase the concentrations of alprazolam, resulting in increased risk of adverse reactions of alprazolam [see Clinical Pharmacology (12.3)].Avoid use and consider appropriate dose reduction when alprazolam is coadministered with a moderate or weak CYP3A inhibitor [see Warnings and Precautions (5.5)].Nefazodone, fluvoxamine, cimetidine, erythromycinConcomitant use of CYP3A inducers can increase alprazolam metabolism and therefore can decease plasma levels of alprazolam [see Clinical Pharmacology (12.3)].
Moderate or Weak Inhibit Clinical implication Prevention or management Examples CYP3A Inducers	tors of CYP3A Concomitant use of alprazolam with CYP3A inhibitors may increase the concentrations of alprazolam, resulting in increased risk of adverse reactions of alprazolam [see Clinical Pharmacology (12.3)]. Avoid use and consider appropriate dose reduction when alprazolam is coadministered with a moderate or weak CYP3A inhibitor [see Warnings and Precautions (5.5)]. Nefazodone, fluvoxamine, cimetidine, erythromycin Concomitant use of CYP3A inducers can increase alprazolam metabolism and therefore can decease plasma

Ritonavir

RILONAVI	
Clinical implication	Interactions involving ritonavir and alprazolam are complex and time dependent. Short term administration of ritonavir increased alprazolam exposure due to CYP3A4 inhibition. Following long term treatment of ritonavir (>10 to 14 days), CYP3A4 induction offsets this inhibition. Alprazolam exposure was not meaningfully affected in the presence of ritonavir.
Prevention or management	Reduce alprazolam dosage when ritonavir and alprazolam are initiated concomitantly, or when ritonavir is added to a regimen where alprazolam is stabilized. Increase alprazolam dosage to the target dosage after 10 to 14 days of dosing ritonavir and alprazolam concomitantly. No dosage adjustment of alprazolam is necessary in patients receiving ritonavir for more than 10 to14 days [see Dosage and Administration (2.6)]. Concomitant use of alprazolam with a strong CYP3A inhibitor, except ritonavir, is contraindicated [see Contraindications (4), Warnings and Precautions (5.5)].
Digoxin	
Clinical implication	Increased digoxin concentrations have been reported when alprazolam was given, especially in geriatric patients(>65 years of age).
Prevention or management	In patients on digoxin therapy, measure serum digoxin concentrations before initiating alprazolam. Continue monitoring digoxin serum concentration and toxicity frequently. Reduce the digoxin dose if necessary.

7.2 Drug/Laboratory Test Interactions

Although interactions between benzodiazepines and commonly employed clinical laboratory tests have occasionally been reported, there is no consistent pattern for a specific drug or specific test.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Exposure Registry

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to psychiatric medications, including alprazolam, during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/research/pregnancyregistry/.

Risk Summary

Neonates born to mothers using benzodiazepines late in pregnancy have been reported to experience symptoms of sedation and/or neonatal withdrawal [see Warnings and *Precautions (5.8) and Clinical Considerations)*]. Available data from published

observational studies of pregnant women exposed to benzodiazepines do not report a clear association with benzodiazepines and major birth defects (see Data).

The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Clinical Considerations

Fetal/Neonatal adverse reactions

Benzodiazepines cross the placenta and may produce respiratory depression, hypotonia, and sedation in neonates. Monitor neonates exposed to alprazolam during pregnancy or labor for signs of sedation, respiratory depression, hypotonia, and feeding problems. Monitor neonates exposed to alprazolam during pregnancy for signs of withdrawal. Manage these neonates accordingly [see Warnings and Precautions (5.8)].

Data

Human Data

Published data from observational studies on the use of benzodiazepines during pregnancy do not report a clear association with benzodiazepines and major birth defects. Although early studies reported an increased risk of congenital malformations with diazepam and chlordiazepoxide, there was no consistent pattern noted. In addition, the majority of recent case-control and cohort studies of benzodiazepine use during pregnancy, which were adjusted for confounding exposures to alcohol, tobacco, and other medications, have not confirmed these findings.

8.2 Lactation

Risk Summary

Limited data from published literature reports the presence of alprazolam in human breast milk. There are reports of sedation, poor feeding and poor weight gain in infants exposed to benzodiazepines through breast milk. The effects of alprazolam on lactation are unknown.

Because of the potential for serious adverse reactions, including sedation and withdrawal symptoms in breastfed infants, advise patients that breastfeeding is not recommended during treatment with alprazolam.

8.4 Pediatric Use

Safety and effectiveness of alprazolam have not been established in pediatric patients.

8.5 Geriatric Use

Alprazolam-treated geriatric patients had higher plasma concentrations of alprazolam (due to reduced clearance) compared to younger adult patients receiving the same doses. Therefore, dosage reduction of alprazolam is recommended in geriatric patients [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)].

8.6 Hepatic Impairment

Patients with alcoholic liver disease exhibit a longer elimination half-life (19.7 hours), compared to healthy subjects (11.4 hours). This may be caused by decreased clearance of alprazolam in patients with alcoholic liver disease. Dosage reduction of alprazolam is recommended in patients with hepatic impairment [see Dosage and Administration (2.4), *Clinical Pharmacology* (12.3)].

9 DRUG ABUSE AND DEPENDENCE

9.1 Controlled Substance

Alprazolam is a Schedule IV controlled substance.

9.2 Abuse

Alprazolam is a benzodiazepine and a CNS depressant with a potential for abuse and addiction. Abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects. Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed. Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence. Even taking benzodiazepines as prescribed may put patients at risk for abuse and misuse of their medication. Abuse and misuse of benzodiazepines may lead to addiction.

Abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death. Benzodiazepines are often sought by individuals who abuse drugs and other substances, and by individuals with addictive disorders [see Warnings and Precautions (5.2)].

The following adverse reactions have occurred with benzodiazepine abuse and/or misuse: abdominal pain, amnesia, anorexia, anxiety, aggression, ataxia, blurred vision, confusion, depression, disinhibition, disorientation, dizziness, euphoria, impaired concentration and memory, indigestion, irritability, muscle pain, slurred speech, tremors, and vertigo.

The following severe adverse reactions have occurred with benzodiazepine abuse and/or misuse: delirium, paranoia, suicidal ideation and behavior, seizures, coma, breathing difficulty, and death. Death is more often associated with polysubstance use (especially benzodiazepines with other CNS depressants such as opioids and alcohol).

9.3 Dependence

Alprazolam may produce physical dependence from continued therapy. Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug. Abrupt discontinuation or rapid

dosage reduction of benzodiazepines or administration of flumazenil, a benzodiazepine antagonist, may precipitate acute withdrawal reactions, including seizures, which can be life-threatening. Patients at an increased risk of withdrawal adverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages (i.e., higher and/or more frequent doses) and those who have had longer durations of use [see Warnings and Precautions (5.3)].

To reduce the risk of withdrawal reactions, use a gradual taper to discontinue alprazolam or reduce the dosage [see Dosage and Administration (2.3), Warnings and Precautions (5.3)].

Acute Withdrawal Signs and Symptoms

Acute withdrawal signs and symptoms associated with benzodiazepines have included abnormal involuntary movements, anxiety, blurred vision, depersonalization, depression, derealization, dizziness, fatigue, gastrointestinal adverse reactions (e.g., nausea, vomiting, diarrhea, weight loss, decreased appetite), headache, hyperacusis, hypertension, irritability, insomnia, memory impairment, muscle pain and stiffness, panic attacks, photophobia, restlessness, tachycardia, and tremor. More severe acute withdrawal signs and symptoms, including life-threatening reactions, have included catatonia, convulsions, delirium tremens, depression, hallucinations, mania, psychosis, seizures, and suicidality.

Protracted Withdrawal Syndrome

Protracted withdrawal syndrome associated with benzodiazepines is characterized by anxiety, cognitive impairment, depression, insomnia, formication, motor symptoms (e.g., weakness, tremor, muscle twitches), paresthesia, and tinnitus that persists beyond 4 to 6 weeks after initial benzodiazepine withdrawal. Protracted withdrawal symptoms may last weeks to more than 12 months. As a result, there may be difficulty in differentiating withdrawal symptoms from potential re-emergence or continuation of symptoms for which the benzodiazepine was being used.

Tolerance

Tolerance to alprazolam may develop from continued therapy. Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose). Tolerance to the therapeutic effect of alprazolam may develop; however, little tolerance develops to the amnestic reactions and other cognitive impairments caused by benzodiazepines.

10 OVERDOSAGE

Overdosage of benzodiazepines is characterized by central nervous system depression ranging from drowsiness to coma. In mild to moderate cases, symptoms can include drowsiness, confusion, dysarthria, lethargy, hypnotic state, diminished reflexes, ataxia, and hypotonia. Rarely, paradoxical or disinhibitory reactions (including agitation, irritability, impulsivity, violent behavior, confusion, restlessness, excitement, and talkativeness) may occur. In severe overdosage cases, patients may develop respiratory depression and coma. Overdosage of benzodiazepines in combination with other CNS depressants (including alcohol and opioids) may be fatal [see Warnings and Precautions (5.2)]. Markedly abnormal (lowered or elevated) blood pressure, heart rate, or respiratory rate raise the concern that additional drugs and/or alcohol are involved in the overdosage.

In managing benzodiazepine overdosage, employ general supportive measures, including intravenous fluids and airway management. Flumazenil, a specific benzodiazepine receptor antagonist indicated for the complete or partial reversal of the sedative effects of benzodiazepines in the management of benzodiazepine overdosage, can lead to withdrawal and adverse reactions, including seizures, particularly in the context of mixed overdosage with drugs that increase seizure risk (e.g., tricyclic and tetracyclic antidepressants) and in patients with long-term benzodiazepine use and physical dependency. The risk of withdrawal seizures with flumazenil use may be increased in patients with epilepsy. Flumazenil is contraindicated in patients who have received a benzodiazepine for control of a potentially life-threatening condition (e.g., status epilepticus). If the decision is made to use flumazenil, it should be used as an adjunct to, not as a substitute for, supportive management of benzodiazepine overdosage. See the flumazenil injection Prescribing Information.


Consider contacting the Poison Help Line (1-800-222-1222), or a medical toxicologist for additional overdosage management recommendations.

11 DESCRIPTION

Alprazolam, USP is a triazolo analog of the 1,4 benzodiazepine class of central nervous system-active compounds.

The chemical name of alprazolam is 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo [4,3- α] [1,4] benzodiazepine.

The structural formula is:



C17H13CIN4 M.W. 308.77

Alprazolam, USP is a white to off-white crystalline powder, which is soluble in alcohol but which has no appreciable solubility in water at physiological pH.

Each alprazolam tablet, USP, for oral administration, contains 0.25, 0.5, 1 or 2 mg of alprazolam, USP.

Inactive ingredients: docusate sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, pregelatinized starch, and sodium benzoate. Additionally, the **0.5 mg** also contains FD&C Yellow #6 Aluminum Lake, and the **1 mg** also contains FD&C Blue #2 Aluminum Lake.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Alprazolam is a 1,4 benzodiazepine. Alprazolam exerts its effect for the acute treatment of generalized anxiety disorder and panic disorder through binding to the benzodiazepine site of gamma-aminobutyric acid-A (GABA_A) receptors in the brain and enhances GABA-mediated synaptic inhibition.

12.3 Pharmacokinetics

Plasma levels of alprazolam increase proportionally to the dose over the range of 0.5 to 3.0 mg.

Absorption

Following oral administration, peak plasma concentration of alprazolam (C_{max}) occurs in 1 to 2 hours post dose.

Distribution

Alprazolam is 80% bound to human serum protein, and albumin accounts for the majority of the binding.

Elimination

The mean plasma elimination half-life ($T_{1/2}$) of alprazolam is approximately 11.2 hours (range: 6.3 to 26.9 hours) in healthy adults.

Metabolism

Alprazolam is extensively metabolized in humans, primarily by cytochrome P450 3A4 (CYP3A4), to 2 major active metabolites in the plasma: 4-hydroxyalprazolam and α - hydroxyalprazolam. The plasma circulation levels of the two active metabolites are less than 4% of the parent. The reported relative potencies in benzodiazepine receptor binding experiments and in animal models of induced seizure inhibition are 0.20 and 0.66, respectively, for 4-hydroxyalprazolam and α -hydroxyalprazolam. The low concentrations and low potencies of 4-hydroxyalprazolam and α -hydroxyalprazolam. A benzophenone derived from alprazolam is also found in humans. Their half-lives appear to be similar to that of alprazolam.

Excretion

Alprazolam and its metabolites are excreted primarily in the urine.

Specific Populations

Geriatric Patients

The mean $T_{1/2}$ of alprazolam was 16.3 hours (range: 9.0 to 26.9 hours) in healthy elderly subjects compared to 11.0 hours (range: 6.3 to -15.8 hours, n=16) in healthy younger adult subjects.

Obese Patients

The mean $T_{1/2}$ of alprazolam was 21.8 hours (range: 9.9 to 40.4 hours) in a group of obese subjects.

Patients with Hepatic Impairment

The mean $T_{1/2}$ of alprazolam was 19.7 hours (range: 5.8 to 65.3 hours) in patients with alcoholic liver disease.

Racial or Ethnic Groups

Maximal concentrations and $T_{1/2}$ of alprazolam are approximately 15% and 25% higher in Asians compared to Caucasians.

Smoking

Alprazolam concentrations may be reduced by up to 50% in smokers compared to nonsmokers.

Drug Interaction Studies

In Vivo Studies

Most of the interactions that have been documented with alprazolam are with drugs that modulate CYP3A4 activity.

Compounds that are inhibitors or inducers of CYP3A would be expected to increase or decrease plasma alprazolam concentrations, respectively. Drug products that have been studied *in vivo*, along with their effect on increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.66 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold [see Contraindications (4), Warnings and Precautions (5.5), Drug Interactions (7.2)]. Other studied drugs include:

<u>Cimetidine</u>

Coadministration of cimetidine increased the maximum plasma concentration of alprazolam by 82%, decreased clearance by 42%, and increased T_{1/2} by 16%. <u>Fluoxetine</u>

Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased T_{1/2} by 17%, and decreased measured psychomotor performance.

Oral Contraceptives

Coadministration of oral contraceptives increased the maximum plasma concentration of alprazolam by 18%, decreased clearance by 22%, and increased $T_{1/2}$ by 29%.

<u>Carbamazepine</u>

The oral clearance of alprazolam (given in a 0.8 mg single dose) was increased from 0.90±0.21 mL/min/kg to 2.13±0.54 mL/min/kg and the elimination $T_{1/2}$ was shortened (from 17.1±4.9 to 7.7±1.7 hour) following administration of 300 mg per day carbamazepine for 10 days [see Drug Interactions (7.2)]. However, the

carbamazepine dose used in this study was fairly low compared to the recommended doses (1000 to 1200 mg per day); the effect at usual carbamazepine doses is unknown.

<u>Ritonavir</u>

Interactions involving HIV protease inhibitors (e.g., ritonavir) and alprazolam are complex and time dependent. Short-term low doses of ritonavir (4 doses of 200 mg) increased mean AUC of alprazolam by about 2.5-fold, and did not significantly affect C_{max} of alprazolam. The elimination $T_{1/2}$ was prolonged (30 hours versus 13 hours). However, upon extended exposure to ritonavir (500 mg, twice daily for 10 days), CYP3A induction offset this inhibition. Alprazolam AUC and C_{max} was reduced by 12% and 16%, respectively, in the presence of ritonavir. The elimination $T_{1/2}$ of alprazolam was not significantly changed [see Warnings and Precautions (5.5)].

<u>Sertraline</u>

A single dose of alprazolam 1 mg and steady state dose of sertraline (50 mg to 150 mg per day) did not reveal any clinically significant changes in the pharmacokinetics of alprazolam.

Imipramine and Desipramine

The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam in doses up to 4 mg per day. *Warfarin*

Alprazolam did not affect the prothrombin or plasma warfarin levels in male volunteers administered sodium warfarin orally.

In Vitro Studies

Data from *in vitro* studies of alprazolam suggest a possible drug interaction of alprazolam with paroxetine. The ability of alprazolam to induce human hepatic enzyme systems has not yet been determined.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

No evidence of carcinogenic potential was observed in rats or mice administered alprazolam for 2-years at doses up to 30 and 10 mg/kg day respectively. These doses are 29 times and 4.8 times the maximum recommended human dose of 10 mg/day based on mg/m² body surface area, respectively.

Mutagenesis

Alprazolam was negative in the *in vitro* Ames bacterial reverse mutation assay and DNA Damage/Alkaline Elution Assay and *in vivo* rat micronucleus genetic toxicology assays.

Impairment of Fertility

Alprazolam produced no impairment of fertility in rats at doses up to 5 mg/kg per day, which is approximately 5 times the maximum recommended human dose of 10 mg per day based on mg/m² body surface area.

13.2 Animal Toxicology and/or Pharmacology

When rats were treated with alprazolam at oral doses of 3 mg, 10 mg, and 30 mg/kg day (3 to 29 times the maximum recommended human dose based on mg/m² body surface area) for 2 years, a tendency for a dose related increase in the number of cataracts was observed in females and a tendency for a dose related increase in corneal vascularization was observed in males. These lesions did not appear until after 11 months of treatment.

14 CLINICAL STUDIES

14.1 Generalized Anxiety Disorder

Alprazolam was compared to placebo in double-blind clinical studies (doses up to 4 mg per day) in patients with a diagnosis of anxiety or anxiety with associated depressive symptomatology. Alprazolam was significantly better than placebo at each of the evaluation periods of these 4-week studies as judged by the following psychometric instruments: Physician's Global Impressions, Hamilton Anxiety Rating Scale, Target Symptoms, Patient's Global Impressions, and Self-Rating Symptom Scale.

14.2 Panic Disorder

The effectiveness of alprazolam in the treatment of panic disorder was studied in 3 short-term, placebo-controlled studies (up to 10 weeks) in patients with diagnoses closely corresponding to DSM-III-R criteria for panic disorder.

The average dose of alprazolam was 5 mg to 6 mg per day in 2 of the studies, and the doses of alprazolam were fixed at 2 mg and 6 mg per day in the third study. In all 3 studies, alprazolam was superior to placebo on a variable defined as "the number of patients with zero panic attacks" (range, 37% to 83% met this criterion), as well as on a global improvement score. In 2 of the 3 studies, alprazolam was superior to placebo on a variable defined as "change from baseline on the number of panic attacks per week" (range, 3.3 to 5.2), and also on a phobia rating scale. A subgroup of patients who improved on alprazolam during short-term treatment in 1 of these trials was continued on an open basis up to 8 months, without apparent loss of benefit.

16 HOW SUPPLIED/STORAGE AND HANDLING

Alprazolam tablets, USP for oral administration are in the following strengths and package configurations:

Alprazolam Tablets			
Package Configuration	Tablet Strength (mg)	NDC	Print
Bottles of 100 Bottles of 500 Bottles of 1000	0.25 mg	NDC 0781-1061-01 NDC 0781-1061-05 NDC 0781-1061-10	Oval, white tablets debossed "GG 256" on one side and scored on the reverse side
Bottles of 100	0.5 mg	NDC 0781-1077-01	Oval, peach tablets

Bottles of 500 Bottles of 1000		NDC 0781-1077-05 NDC 0781-1077-10	debossed "GG 257" on one side and scored on the reverse side
Bottles of 100 Bottles of 500 Bottles of 1000	1 mg	NDC 0781-1079-01 NDC 0781-1079-05 NDC 0781-1079-10	Oval, blue tablets debossed "GG 258" on one side and scored on the reverse side
Bottles of 100 Bottles of 500	2 mg	NDC 0781-1089-01 NDC 0781-1089-05	Rectangular white multi-scored tablets debossed "GG 249" on one side and plain on the reverse side

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

Dispense contents in a tight, light-resistant container as defined in the USP with a child-resistant closure.

KEEP OUT OF THE REACH OF CHILDREN.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Risks from Concomitant Use with Opioids

Advise both patients and caregivers about the risks of potentially fatal respiratory depression and sedation when alprazolam is used with opioids and not to use such drugs concomitantly unless supervised by a healthcare provider. Advise patients not to drive or operate heavy machinery until the effects of concomitant use with the opioid have been determined [see Warnings and Precautions (5.1), Drug Interactions (7.1)].

Abuse, Misuse, and Addiction

Inform patients that the use of alprazolam, even at recommended dosages, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose and death, especially when used in combination with other medications (e.g., opioid analgesics), alcohol, and/or illicit substances. Inform patients about the signs and symptoms of benzodiazepine abuse, misuse, and addiction; to seek medical help if they develop these signs and/or symptoms; and on the proper disposal of unused drug [see Warnings and Precautions (5.2), Drug Abuse and Dependence (9.2)].

Withdrawal Reactions

Inform patients that the continued use of alprazolam may lead to clinically significant physical dependence and that abrupt discontinuation or rapid dosage reduction of alprazolam may precipitate acute withdrawal reactions, which can be life-threatening. Inform patients that in some cases, patients taking benzodiazepines have developed a protracted withdrawal syndrome with withdrawal symptoms lasting weeks to more than 12 months. Instruct patients that discontinuation or dosage reduction of alprazolam may require a slow taper [see Warnings and Precautions (5.3), Drug Abuse and Dependence (9.3)].

Effects on Driving and Operating Machinery

Advise patients not to drive a motor vehicle or operate heavy machinery while taking alprazolam due to its CNS depressant effects. Also advise patients to avoid use of alcohol or other CNS depressants while taking alprazolam [see Warnings and *Precautions (5.3)*].

Patients with Depression

Advise patients, their families, and caregivers to look for signs of suicidality or worsening depression, and to inform the patient's healthcare provider immediately [see Warnings and Precautions (5.6)].

Concomitant Medications

Advise patients to inform their healthcare provider of all medicines they take, including prescription and nonprescription medications, vitamins and herbal supplements [see Drug Interactions (7)].

Pregnancy

Advise pregnant females that use of alprazolam late in pregnancy can result in sedation (respiratory depression, lethargy, hypotonia) and/or withdrawal symptoms (hyperreflexia, irritability, restlessness, tremors, inconsolable crying, and feeding difficulties) in newborns [see Warnings and Precautions (5.8), Use in Specific Populations (8.1)]. Instruct patients to inform their healthcare provider if they are pregnant.

Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to alprazolam during pregnancy [see Use in Specific Populations (8.1)].

Lactation

Advise patients that breastfeeding is not recommended during treatment with alprazolam [see Use in Specific Populations (8.2)].

This product's labeling may have been updated. For the most recent prescribing information, please visit www.sandoz.com.

MEDICATION GUIDE Alprazolam Tablets, USP CIV (al PRAY zoe lam)

What is the most important information I should know about alprazolam tablets?

 Alprazolam tablets are a benzodiazepine medicine. Taking benzodiazepines with opioid medicines, alcohol, or other central nervous system (CNS) depressants (including street drugs) can cause severe drowsiness, breathing problems (respiratory depression), coma and death.

Get emergency help right away if any of the following happens:

- shallow or slowed breathing
- breathing stops (which may lead to the heart stopping)
- $\bigcirc\$ excessive sleepiness (sedation)

Do not drive or operate heavy machinery until you know how taking alprazolam tablets with opioids affects you.

- **Risk of abuse, misuse, and addiction**. There is a risk of abuse, misuse, and addiction with benzodiazepines, including alprazolam tablets, which can lead to overdose and serious side effects including coma and death.
- Serious side effects including coma and death have happened in people who have abused or misused benzodiazepines, including alprazolam tablets. These serious side effects may also include delirium, paranoia, suicidal thoughts or actions, seizures, and difficulty breathing. Call your healthcare provider or go to the nearest hospital emergency room right away if you get any of these serious side effects.
- You can develop an addiction even if you take alprazolam tablets as prescribed by your healthcare provider.
- \odot Take alprazolam tablets exactly as your healthcare provider prescribed.
- \bigcirc Do not share your alprazolam tablets with other people.
- $\odot\;$ Keep alprazolam tablets in a safe place and away from children.
- **Physical dependence and withdrawal reactions.** Alprazolam tablets can cause physical dependence and withdrawal reactions.
- O Do not suddenly stop taking alprazolam tablets. Stopping alprazolam tablets suddenly can cause serious and life-threatening side effects, including, unusual movements, responses, or expressions, seizures, sudden and severe mental or nervous system changes, depression, seeing or hearing things that others do not see or hear, an extreme increase in activity or talking, losing touch with reality, and suicidal thoughts or actions. Call your healthcare provider or go to the nearest hospital emergency room right away if you get any of these symptoms.
- Some people who suddenly stop benzodiazepines, have symptoms that can last for several weeks to more than 12 months, including, anxiety, trouble remembering, learning, or concentrating, depression, problems sleeping, feeling like insects are crawling under your skin, weakness, shaking, muscle twitching, burning or prickling feeling in your hands, arms, legs or feet, and ringing in your ears.
- Physical dependence is not the same as drug addiction. Your healthcare provider can tell you more about the differences between physical dependence and drug addiction.
- Do not take more alprazolam tablets than prescribed or take alprazolam tablets for longer than prescribed.

What are alprazolam tablets?

- Alprazolam tablets are a prescription medicine used:
- \bigcirc to treat anxiety disorders
- $\odot\,$ for the short-term relief of the symptoms of anxiety
- to treat panic disorder with or without a fear of places and situations that might cause panic, helplessness, or embarrassment (agoraphobia)

- Alprazolam tablets are a federal controlled substance (C-IV) because it can be abused or lead to dependence. Keep alprazolam tablets in a safe place to prevent misuse and abuse. Selling or giving away alprazolam tablets may harm others, and is against the law. Tell your healthcare provider if you have abused or been dependent on alcohol, prescription medicines or street drugs.
- It is not known if alprazolam tablets are safe and effective in children.
- Elderly patients are especially susceptible to dose related adverse effects when taking alprazolam tablets.
- It is not known if alprazolam tablets are safe and effective when used to treat anxiety disorder for longer than 4 months.
- It is not known if alprazolam tablets are safe and effective when used to treat panic disorder for longer than 10 weeks.

Do not take alprazolam tablets if:

- you are allergic to alprazolam, other benzodiazepines, or any of the ingredients in alprazolam tablets. See the end of this Medication Guide for a complete list of ingredients in alprazolam tablets.
- you are taking antifungal medicines including ketoconazole and itraconazole.

Before you take alprazolam tablets, tell your healthcare provider about all of your medical conditions, including if you:

- have or have had depression, mood problems, or suicidal thoughts or behavior
- have liver or kidney problems
- have lung disease or breathing problems
- are pregnant or plan to become pregnant.
- Taking alprazolam tablets late in pregnancy may cause your baby to have symptoms of sedation (breathing problems, sluggishness, low muscle tone), and/or withdrawal symptoms (jitteriness, irritability, restlessness, shaking, excessive crying, feeding problems).
- Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with alprazolam tablets.
- There is a pregnancy registry for women who take alprazolam tablets during pregnancy. The purpose of the registry is to collect information about the health of you and your baby. If you become pregnant during treatment with alprazolam tablets, talk to your healthcare provider about registering with the National Pregnancy Registry for Psychiatric Medications. You can register by calling 1-866-961-2388 or visiting https://womensmentalhealth.org/pregnancyregistry/.
- are breastfeeding or plan to breastfeed. Alprazolam passes into your breast milk.
- Talk to your healthcare provider about the best way to feed your baby if you take alprazolam tablets.
- Breastfeeding is not recommended during treatment with alprazolam tablets.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking alprazolam tablets with certain other medicines can cause side effects or affect how well alprazolam tablets or the other medicines work. Do not start or stop other medicines without talking to your healthcare provider.

How should I take alprazolam tablets?

- See "What is the most important information I should know about alprazolam tablets?"
- Take alprazolam tablets exactly as your healthcare provider tells you to take them. Your healthcare provider will tell you how many alprazolam tablets to take and when to take them.
- If you take too many alprazolam tablets, call your healthcare provider or go to the nearest hospital emergency room right away.

What are the possible side effects of alprazolam tablets? Alprazolam tablets may cause serious side effects, including:

- See "What is the most important information I should know about alprazolam tablets?"
- **Seizures.** Stopping alprazolam tablets can cause seizures and seizures that will not stop (status epilepticus).
- Mania. Alprazolam tablets may cause an increase in activity and talking (hypomania and mania) in people who have depression.
 - O Alprazolam tablets can make you sleepy or dizzy and can slow your thinking and motor skills. Do not drive, operate heavy machinery, or do other dangerous activities until you know how alprazolam tablets affect you.
 - O Do not drink alcohol or take other drugs that may make you sleepy or dizzy while taking alprazolam tablets without first talking to your healthcare provider. When taken with alcohol or drugs that cause sleepiness or dizziness, alprazolam tablets may make your sleepiness or dizziness much worse.

The most common side effects of alprazolam tablets include:

- problems with coordination
- hypotension
- trouble saying words clearly (dysarthria)
- changes in sex drive (libido)

These are not all the possible side effects of alprazolam tablets. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store alprazolam tablets?

- Store alprazolam tablets between 68° to 77°F (20° to 25°C)
- Keep Alprazolam tablets and all medicines out of reach of children.

General information about the safe and effective use of alprazolam tablets.

- Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide.
- Do not use alprazolam tablets for a condition for which they were not prescribed.
- Do not give alprazolam tablets to other people, even if they have the same symptoms that you have. They may harm them.
- You can ask your pharmacist or healthcare provider for information about alprazolam tablets that is written for health professionals.

What are the ingredients in alprazolam tablets? Active ingredient: alprazolam

Inactive ingredients: docusate sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, pregelatinized starch, and sodium benzoate. Additionally, the 0.5 mg also contains FD&C Yellow #6 Aluminum Lake, and the 1 mg also contains FD&C Blue #2 Aluminum Lake.

This Medication Guide has been approved by the U.S. Food and Drug Administration.

Manufactured by

Sandoz Inc.

Princeton, NJ 08540

46299643

MF42029400REV11/23

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL

NDC 0781-1061-01

Alprazolam

Tablets, USP CIV


0.25 mg

Rx only

PHARMACIST: Dispense the Medication Guide provided separately to each patient.

100 Tablets

SANDOZ



0.5 mg Label

NDC 0781-1077-01

Alprazolam

Tablets, USP CIV


0.5 mg

Rx only

PHARMACIST: Dispense the Medication Guide provided separately to each patient.

100 Tablets

SANDOZ



1 mg Label

NDC0781-1079-01

Alprazolam

Tablets, USP CIV


1 mg

Rx only

PHARMACIST: Dispense the Medication Guide provided separately to each patient.

100 Tablets

SANDOZ



2 mg Label

NDC0781-1089-01

Alprazolam

Tablets, USP CIV


2 mg

Rx only

PHARMACIST: Dispense the Medication Guide provided separately to each patient.

100 Tablets

SANDOZ



	orazolam tablet	-						
Ρ	roduct Infor	matio	on					
P	roduct Type		HUMAN PRES	SCRIPTION DRUG	ltem Co	de (Source)	NE	DC:0781-106
R	oute of Admini	istrati	on ORAL		DEA Sch	nedule	Cľ	V
A	ctive Ingredi	ent/A	Active Moiety					
			Ingredient Nam	e		Basis of S	trength	Strength
AL	PRAZOLAM (UNII	I: YU55	MQ3IZY) (ALPRAZOLA	M - UNII:YU55MQ3	IZY)	ALPRAZ OLAM		.25 mg
lr	nactive Ingre	dient	ts					
				ent Name			S	trength
M	ICROCRYSTALLII		LULOSE (UNII: OP1R	32D61U)				
D	OCUSATE SODIU	M (UNI	I: F05Q2T2JA0)					
LÆ	CTOSE MONOH	YDRAT	E (UNII: EWQ57Q8I5X))				
M	AGNESIUM STEA	RATE	(UNII: 70097M6I30)					
50	DDIUM BENZOAT	E (UNI	I: OJ245FE5EU)					
ST	TARCH, CORN (UI	NII: 082	232NY3SJ)					
-		_						
	roduct Chara	acter	ISTICS					
~				C			2 min n	
	blor			Sco			2 piec	es
sI	hape		WHITE (WHITE) OVAL (OVAL)	Size	•		9mm	
SI Fl	hape avor			Size		2		
SI FI	hape			Size	•	5	9mm	
SI FI Ca	hape avor			Size	rint Code		9mm GG256	5
SI FI Ca	hape avor ontains ackaging			Size	rint Code	e rketing Start Date	9mm GG256 Marke	
SI FI Co P	hape avor ontains ackaging Item Code	100 in Produc	OVAL (OVAL) Package Des 1 BOTTLE; Type 0: N	Size Imp	rint Code	rketing Start Date	9mm GG256 Marke	eting End Date
SI FI Ca P #	hape avor ontains ackaging Item Code NDC:0781-1061- 01 NDC:0781-1061- 05	Production Production	OVAL (OVAL) Package Des 1 BOTTLE; Type 0: N ct 1 BOTTLE; Type 0: N ct	scription lot a Combination	mint Code Ma 12/29, 12/29,	rketing Start Date /1995	9mm GG256 Marke	eting End Date
SI FI C # 1 2	hape avor ontains ackaging Item Code NDC:0781-1061- 01 NDC:0781-1061- 05	Production Production	OVAL (OVAL) Package Des 1 BOTTLE; Type 0: N ct 1 BOTTLE; Type 0: N ct n 1 BOTTLE; Type 0: N	scription lot a Combination	mint Code Ma 12/29, 12/29,	rketing Start Date /1995 /1995	9mm GG250 Marke 1 03/19/202	eting End Date 27 27
SI FI Ca	hape avor ontains ackaging Item Code NDC:0781-1061- 01 NDC:0781-1061- 05 NDC:0781-1061-	Production Productina Productina Productina Productina Productina Productina	OVAL (OVAL) Package Des 1 BOTTLE; Type 0: N ct 1 BOTTLE; Type 0: N ct n 1 BOTTLE; Type 0: N	scription lot a Combination	mint Code Ma 12/29, 12/29,	rketing Start Date /1995 /1995	9mm GG256 Marke 03/19/202 03/19/202	eting End Date 27 27
SI FI C 7 # 1 2 3	hape avor ontains ackaging Item Code NDC:0781-1061- 01 NDC:0781-1061- 05 NDC:0781-1061-	Product 500 in Product 1000 in Product	OVAL (OVAL) Package Des 1 BOTTLE; Type 0: N ct 1 BOTTLE; Type 0: N ct in 1 BOTTLE; Type 0: N ct	scription lot a Combination	mint Code Ma 12/29, 12/29,	rketing Start Date /1995 /1995	9mm GG256 Marke 03/19/202 03/19/202	eting End Date 27
SI FI C 7 # 1 2 3	hape avor ontains ackaging Item Code NDC:0781-1061- 01 NDC:0781-1061- 05 NDC:0781-1061- 10	Product 500 in Product 1000 i Product	OVAL (OVAL) Package Des 1 BOTTLE; Type 0: N ct 1 BOTTLE; Type 0: N ct in 1 BOTTLE; Type 0: N ct	Size Imp cription lot a Combination lot a Combination Not a Combination	mint Code Ma 12/29 12/29	rketing Start Date /1995 /1995	9mm GG256 03/19/202 03/19/202 03/19/202	eting End Date 27 27

Ρ	roduct Inform	mation							
Pı	roduct Type		HUMAN PRESCRIPTION DRU	G Ite	em Code	(Source)		NDC	C:0781-107
R	oute of Adminis	stration	ORAL	DE	A Sched	ule		CIV	
4	ctive Ingredie	ent/Active	Moiety						
		Ingre	dient Name			Basis of S	treng	th	Strengt
AL.	.PRAZOLAM (UNII:	YU55MQ3IZY)	(ALPRAZ OLAM - UNII:YU55M	Q3IZY)		ALPRAZ OLAM			.5 mg
In	active Ingree	dients							
			Ingredient Name					Sti	rength
М	ICROCRYSTALLIN	E CELLULOSE	(UNII: OP1R32D61U)						
	DCUSATE SODIUI								
	D&C YELLOW NO								
	CTOSE MONOHY								
	AGNESIUM STEAI	RATE (UNII: 700							
	DDIUM BENZOAT	E (UNII: OJ245F	E5EU)						
ST Pi	DDIUM BENZOAT FARCH, CORN (UN FODUCT Chara	E (UNII: 0J245F III: 08232NY35 Cteristics	E5EU) J)	Scor	e		2	2 piece	25
ST Pi	DDIUM BENZOAT FARCH, CORN (UN FODUCT Chara	E (UNII: OJ245F III: O8232NY3S	E5EU) J) (PEACH)	Scor Size	e			2 piece 9mm	25
ST Pi Co Sł	DDIUM BENZOAT FARCH, CORN (UN FODUCT Chara	E (UNII: OJ245F III: O8232NY35 Cteristics ORANGE	E5EU) J) (PEACH)	Size	e int Code		9	•	
ST Pi Ca Sh	DDIUM BENZOAT FARCH, CORN (UN roduct Chara plor hape	E (UNII: OJ245F III: O8232NY35 Cteristics ORANGE	E5EU) J) (PEACH)	Size	-		9)mm	
ST Pi Ca Sh Fli	DDIUM BENZOAT FARCH, CORN (UN roduct Chara blor hape avor	E (UNII: OJ245F III: O8232NY35 Cteristics ORANGE	E5EU) J) (PEACH)	Size	int Code		9 G	9mm 9G257	,
Pi Co Fli Co Pi	DDIUM BENZOAT FARCH, CORN (UN roduct Chara plor hape avor pontains	E (UNII: OJ245F III: 08232NY3S Cteristics ORANGE OVAL (OV	E5EU) J) (PEACH)	Size	int Code Marke	ting Start Date	9 G	omm GG257	
PI Co FI Co Pi	odium BENZOAT FARCH, CORN (UN roduct Chara olor hape avor ontains ackaging Item Code	E (UNII: OJ245F III: O8232NY3S Cteristics ORANGE OVAL (OV	E5EU) J) (PEACH) 'AL)	Size Impr	int Code Marke	eting Start Date	9 G Ma	omm GG257	, ting End ate
Pi Co Fli Co Pi	ARCH, CORN (UN roduct Chara olor hape avor ontains ackaging item Code NDC:0781-1077- 01 NDC:0781-1077- 05	E (UNII: OJ245F III: O8232NY3S Cteristics ORANGE OVAL (OV Pac 100 in 1 BOTT Product 500 in 1 BOTT Product	E5EU) J) (PEACH) AL) AL) LE; Type 0: Not a Combination LE; Type 0: Not a Combination	Size Impr	int Code Marke	e ting Start Date	9 G Ma 03/19	omm GG257 Arket	ting End ate
Pi Cc Fli Cc Pi #	ARCH, CORN (UN roduct Chara olor hape avor ontains ackaging item Code NDC:0781-1077- 01 NDC:0781-1077- 05 NDC:0781-1077-	E (UNII: OJ245F III: O8232NY3S Cteristics ORANGE OVAL (OV Pac 100 in 1 BOTT Product 500 in 1 BOTT Product	E5EU) J) (PEACH) 'AL) C kage Description LE; Type 0: Not a Combinatio	Size Impr	Marke	eting Start Date	9 G Ma 03/19	arket D/2027	ting End ate
ST Pi CC Pi # 1	ARCH, CORN (UN roduct Chara olor hape avor ontains ackaging item Code NDC:0781-1077- 01 NDC:0781-1077- 05 NDC:0781-1077- 10	E (UNII: OJ245F III: O8232NY3S ORANGE OVAL (OV Pac 100 in 1 BOTT Product 1000 in 1 BOTT Product 1000 in 1 BOTT Product	E5EU) J) (PEACH) AL) AL) Ckage Description LE; Type 0: Not a Combination LE; Type 0: Not a Combination LE; Type 0: Not a Combination	Size Impr	Marke 12/29/199	eting Start Date	9 G Ma 03/19	arket D/2027	ting End ate
PICCC	ARCH, CORN (UN roduct Chara olor hape avor ontains ackaging item Code NDC:0781-1077- 01 NDC:0781-1077- 10	E (UNII: OJ245F III: O8232NY3S Cteristics ORANGE OVAL (OV Pac 100 in 1 BOTT Product 1000 in 1 BOTT Product 1000 in 1 BOTT Product	E5EU) J) (PEACH) AL) AL) LE; Type 0: Not a Combination LE; Type 0: Not a Combination LE; Type 0: Not a Combination TLE; Type 0: Not a Combination TLE; Type 0: Not a Combination	Size Impr on on	Marke 12/29/199 12/29/199	eting Start Date 95 95	9 G 03/19 03/19	9/2027 9/2027	ting End ate
P C C C C C C C C C C C C C C C C C C C	ARCH, CORN (UN roduct Chara olor hape avor ontains ackaging item Code NDC:0781-1077- 01 NDC:0781-1077- 05 NDC:0781-1077- 10	E (UNII: OJ245F III: O8232NY3S Cteristics ORANGE OVAL (OV Pac 100 in 1 BOTT Product 1000 in 1 BOTT Product 1000 in 1 BOTT Product	ESEU) J) (PEACH) AL) AL) Ckage Description LE; Type 0: Not a Combination LE; Type 0: Not a Combination Citation	Size Impr on on	Marke 12/29/199 12/29/199	eting Start Date 95 95 95 95 95	9 G 03/19 03/19 03/19	arket 0/2027 0/2027	ting End ate 7 7 7

Ρ	roduct Infor	mation	I					
P	roduct Type		HUMAN PRES	CRIPTION DRUG	Item Coc	le (Source)	N	IDC:0781-107
Route of Administration		ORAL	ORAL DE		EA Schedule		CIV	
A	ctive Ingredi	ent/Act	tive Moiety					
		lı	ngredient Nam	е		Basis of St	trength	Strength
AL	.PRAZOLAM (UNI	I: YU55MQ	3IZY) (ALPRAZOLAI	M - UNII:YU55MQ3	IZY)	ALPRAZ OLAM		1 mg
In	active Ingre	dients						
			Ingredie	nt Name			9	Strength
M	CROCRYSTALLI	NE CELLU	JLOSE (UNII: OP1R3	32D61U)				
D	DCUSATE SODIU	M (UNII: F	05Q2T2JA0)					
FC	O&C BLUE NO. 2	(UNII: LOG	5K8R7DQK)					
LA	CTOSE MONOH	YDRATE	(UNII: EWQ57Q8I5X)					
	AGNESIUM STEA		III: 70097M6I30)					
50								
	ARCH, CORN (U		DJ245FE5EU) 2NY3SJ)					
ST	ARCH, CORN (U	NII: 08232	2NY3SJ)					
ST Pi	roduct Chara	NII: 08232 Acterist	2NY3SJ)	Score			2 piec	-05
ST P Ca	roduct Chara	NII: 08232 Acterist	tics LUE (BLUE)	Score	1		2 piec	:es
ST P Ca	roduct Chara	NII: 08232 Acterist	2NY3SJ)	Size			2 piec 9mm GG25	
ST P Ca SI FI	roduct Chara blor nape	NII: 08232 Acterist	tics LUE (BLUE)	Size	nt Code		9mm	
ST Ca St Fl	roduct Chara olor nape avor ontains	NII: 08232 Acterist	tics LUE (BLUE)	Size			9mm	
Pi Ca Fli Ca	roduct Chara blor nape avor	NII: 08232 Acterist	tics LUE (BLUE)	Size Impri	nt Code	keting Start Date	9mm GG25	
ST Ca SH FI Ca Pa	roduct Chara plor hape avor ontains ackaging Item Code	NII: 08232 Acterist B C	2NY3SJ) tics BLUE (BLUE) DVAL (OVAL)	cription	nt Code	Date	9mm GG25	8 ating End Date
P C S F F C C C C	ARCH, CORN (U) roduct Chara olor hape avor ontains ackaging item Code NDC:0781-1079- 01 NDC:0781-1079- 05	100 in 1 Product 500 in 1	ENY3SJ) tics BLUE (BLUE) OVAL (OVAL) Package Des BOTTLE; Type 0: N BOTTLE; Type 0: N	cription ot a Combination ot a Combination	nt Code Mar 12/29/1 12/29/1	Date .995	9mm GG25 Mark	8 Ceting End Date
ST Ca St Fl	ARCH, CORN (U) roduct Chara olor hape avor ontains ackaging item Code NDC:0781-1079- 01 NDC:0781-1079- 05	100 in 1 Product 500 in 1	2NY3SJ) tics BLUE (BLUE) OVAL (OVAL) Package Des BOTTLE; Type 0: N	cription ot a Combination ot a Combination	nt Code Mar 12/29/1 12/29/1	Date .995 .995	9mm GG25 Mark 03/19/20	8 eting End Date 027
ST P C C S F I C C C P 7 # 1	ARCH, CORN (U) roduct Chara olor hape avor ontains ackaging item Code NDC:0781-1079- 01 NDC:0781-1079- 05 NDC:0781-1079-	100 in 1 Product 100 in 1 Product	ENY3SJ) tics BLUE (BLUE) OVAL (OVAL) Package Des BOTTLE; Type 0: N BOTTLE; Type 0: N	cription ot a Combination ot a Combination	nt Code Mar 12/29/1 12/29/1	Date .995 .995	9mm GG25 Mark 03/19/20	8 eting End Date 027 027
ST P C S F I C C C P i # 1 2 3	ARCH, CORN (U) roduct Chara olor hape avor ontains ackaging item Code NDC:0781-1079- 01 NDC:0781-1079- 05 NDC:0781-1079-	100 in 1 Product 100 in 1 Product 1000 in 1 Product	ENY3SJ) tics BLUE (BLUE) DVAL (OVAL) Package Des BOTTLE; Type 0: N BOTTLE; Type 0: N I BOTTLE; Type 0: I	cription ot a Combination ot a Combination	nt Code Mar 12/29/1 12/29/1	Date .995 .995	9mm GG25 Mark 03/19/20	8 eting End Date 027 027
ST P C S F C C P T T 2 3	roduct Chara olor hape avor ontains ackaging item Code NDC:0781-1079- 01 NDC:0781-1079- 05 NDC:0781-1079- 10	Acterist Acterist B C C 100 in 1 Product 500 in 1 Product 1000 in 1 Product	ENY3SJ) tics BLUE (BLUE) DVAL (OVAL) Package Des BOTTLE; Type 0: N BOTTLE; Type 0: N I BOTTLE; Type 0: I	cription ot a Combination ot a Combination Not a Combination	nt Code Mar 12/29/1 12/29/1	Date .995 .995	9mm GG25 Mark 03/19/20 03/19/20	8 eting End Date 027 027

	razolam tablet						
Pı	roduct Infor	mation					
Pr	oduct Type		HUMAN PRESCRIPTION DRUG	ltem	Code (Source)	1	NDC:0781-108
	oute of Admini	stration	ORAL		Schedule		CIV
Ac	tive Ingredi	ent/Active	Moiety				
		Ingre	dient Name		Basis of St	trength	Strengt
AL	PRAZOLAM (UNII	: YU55MQ3IZY)	(ALPRAZ OLAM - UNII:YU55MQ3	IZY)	ALPRAZ OLAM		2 mg
In	active Ingre	dients					
			Ingredient Name				Strength
MI	CROCRYSTALLIN	NE CELLULOSE	E (UNII: OP1R32D61U)				
	CUSATE SODIU		•				
LA	CTOSE MONOH	YDRATE (UNII:	EWQ57Q8I5X)				
	GNESIUM STEA						
so	DIUM BENZOAT	E (UNII: OJ245F	E5EU)				
$\sim -$			I) III III III III III III III III III				
ST.	ARCH, CORN (UI	un. 0025211155	, (
	oduct Chara])				
Pr				5	Score	4	l pieces
Pr Co	oduct Chara lor	Acteristics WHITE (WHITE			Score		l pieces .5mm
Pr Co Sh	oduct Chara	Acteristics WHITE (WHITE	E)	S	Size	1	•
Pr Co Sh Fla	oduct Chara lor ape	Acteristics WHITE (WHITE	E)	S		1	.5mm
Pr Co Sh Fla	oduct Chara lor ape ivor	Acteristics WHITE (WHITE	E)	S	Size	1	.5mm
Pr Co Sh Fla Co	oduct Chara lor ape ivor	Acteristics WHITE (WHITE	E)	S	Size	1	.5mm
Pr Co Sh Fla Co	oduct Chara lor ape ivor ntains	WHITE (WHITE RECTANGLE	E)	S	Size	1	.5mm
Pr Co Sh Fla Co Pa #	oduct Chara lor ape ivor ntains ackaging Item Code	Acteristics WHITE (WHITE RECTANGLE	E) (RECTANBLE)	5	Size mprint Code Marketing Start	1	5mm 5G249 keting End Date
Pr Co Sh Fla Co Pa #	roduct Chara lor ape ivor ntains ackaging Item Code NDC:0781-1089-	Acteristics WHITE (WHITE RECTANGLE Pace 100 in 1 BOTT Product	E) (RECTANBLE) Ckage Description	S I 03	Size mprint Code Marketing Start Date	1 C Marl	5mm 5G249 keting End Date
Pr Co Sh Fla Co Pa #	roduct Chara lor ape ovor ntains ackaging item Code NDC:0781-1089- 01 NDC:0781-1089-	Acteristics WHITE (WHITE RECTANGLE Pace 100 in 1 BOTT Product 500 in 1 BOTT	E) (RECTANBLE) C kage Description 'LE; Type 0: Not a Combination	S I 03	Size mprint Code Marketing Start Date /25/1998	1 C Mari 03/19/2	5mm 5G249 keting End Date
Pr Co Sh Fla Co Pa # 1	roduct Chara lor ape ivor ntains ackaging item Code NDC:0781-1089- 01 NDC:0781-1089- 05	Acteristics WHITE (WHITE RECTANGLE Pace 100 in 1 BOTT Product 500 in 1 BOTT Product	E) (RECTANBLE) Ckage Description LE; Type 0: Not a Combination LE; Type 0: Not a Combination	03 03	Size mprint Code Marketing Start Date /25/1998 /25/1998	1 C Marl 03/19/2 03/19/2	5mm 5G249 keting End Date 027 027
Pr Co Sh Fla Co Pa # 1	roduct Chara lor ape ivor ntains ackaging item Code NDC:0781-1089- 01 NDC:0781-1089- 05	Acteristics WHITE (WHITE RECTANGLE Pace 100 in 1 BOTT Product 500 in 1 BOTT Product	E) (RECTANBLE) Ckage Description LE; Type 0: Not a Combination LE; Type 0: Not a Combination	03 03	Size mprint Code Marketing Start Date /25/1998	1 C Marl 03/19/2 03/19/2	5mm 5G249 keting End Date